Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 2, March-April, p. 219–226

doi: 10.17219/acem/33250

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The Protective Effect of Adalimumab on Renal Injury in a Model of Abdominal Aorta Cross-Clamping

Medine C. Cure1,A,C,D,F, Erkan Cure2,A,B,C,D, Yildiray Kalkan3,C,D,F, Levent Tumkaya3,B,E,F, Ibrahim Aydin4,A,B,E, Aynur Kirbas1,A,B,F, Hasan Efe1,A,E,F, Aysel Kurt5,B,C,E, Suleyman Yuce2,B,C,F

1 Department of Biochemistry, Recep Tayyip Erdogan University, Turkey

2 Department of Internal Medicine, Recep Tayyip Erdogan University, Turkey

3 Department of Histology and Embrylogy, Recep Tayyip Erdogan University, Turkey

4 Department of Surgery, Recep Tayyip Erdogan University, Turkey

5 Department of Thoracic Surgery, Recep Tayyip Erdogan University, Turkey

Abstract

Background. Adalimumab (ADA) is a potent inhibitor of tumor necrosis factor (TNF-α). ADA treatment suppresses proinflammatory cytokines, leading to a decrease or inhibition of the inflammatory process.
Objectives. The aim of this study was to investigate the possible protective effects of ADA on oxidative stress and cellular damage on rat kidney tissue after ischemia/reperfusion (I/R).
Material and Methods. A total of 30 male Wistar albino rats were divided into three groups: control, I/R, and I/R plus ADA (I/R + ADA); each group comprised 10 animals. The control group underwent laparotomy without I/R injury. After undergoing laparotomy, I/R groups underwent two hours of infrarenal abdominal aortic cross ligation, which was followed by two hours of reperfusion. ADA (50 mg/kg) was administered as a single dose, intraperitoneally, to the I/R + ADA group, 5 days before I/R.
Results. The I/R group’s TNF-α (1150.9 ± 145.6 pg/mg protein), IL-1β (287.0 ± 32.4 pg/mg protein) and IL-6 (1085.6 ± 56.7 pg/mg protein) levels were significantly higher than those of the control (916.1 ± 88.7 pg/mg protein, p = 0.003; 187.5 ± 37.2 pg/mg protein, p < 0.001; 881.4 ± 57.1 pg/mg protein, p < 0.001, respectively) and I/R + ADA groups (864.2 ± 169.4 pg/mg protein, p = 0.003; 241.4 ± 33.4 pg/mg protein, p = 0.010; 987.7 ± 66.5 pg/mg protein, p = 0.004, respectively). To date, a few histopathological changes have been reported regarding renal I/R injury in rats due to ADA treatment whereas I/R caused severe histopathological injury to kidney tissue.
Conclusion. ADA treatment significantly attenuated the severity of kidney I/R injury, inhibiting I/R-induced oxidative stress and renal damage. Because of its anti-inflammatory and antioxidant effects, ADA pretreatment may have protective effects on experimental kidney injury.

Key words

ischemia, reperfusion injury, adalimumab, carbonic anhydrases, tumor necrosis factor alpha

References (37)

  1. Kiris I, Tekin I, Yilmaz N, Sutcu R, Karahan N, Ocal A: Iloprost downregulates expression of adhesion molecules and reduces renal injury induced by abdominal aortic ischemia-reperfusion. Ann Vasc Surg 2009, 23, 212–223.
  2. Gulmen S, Kiris I, Narin C, Ceylan BG, Mermi B, Sutcu R, Meteoglu I: Tezosentan reduces the renal injury induced by abdominal aortic ischemia-reperfusion in rats. J Surg Res 2009, 157, 7–13.
  3. Kucuk A, Kabadere S, Tosun M, Koken T, Kinaci MK, Isikli B, Erkasap N: Protective effects of doxycycline in ischemia/reperfusion injury on kidney. J Physiol Biochem 2009, 65, 183–191.
  4. Sener G, Sehirli O, Velioğlu-Oğünç A, Cetinel S, Gedik N, Caner M, Sakarcan A, Yeğen BC: Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res 2006, 54, 65–71.
  5. Patel NS, Chatterjee PK, Di Paola R, Mazzon E, Britti D, De Sarro A, Cuzzocrea S, Thiemermann C: Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfussion. J Pharmacol Exp Ther 2005, 312, 1170–1178.
  6. McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR: Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum 2012, 64, 3129–3138.
  7. Kayakabe K, Kuroiwa T, Sakurai N, Ikeuchi H, Kadiombo AT, Sakairi T, Kaneko Y, Maeshima A, Hiromura K, Nojima Y: Interleukin-1β measurement in stimulated whole blood cultures is useful to predict response to antiTNF therapies in rheumatoid arthritis. Rheumatology (Oxford) 2012, 51, 1639–1643.
  8. Di Paola R, Genovese T, Impellizzeri D, Ahmad A, Cuzzocrea S, Esposito E: The renal injury and inflammation caused by ischemia-reperfusion are reduced by genetic inhibition of TNF-αR1: A comparison with infliximab treatment. Eur J Pharmacol 2013, 700, 134–146.
  9. Tasdemir C, Tasdemir S, Vardi N, Ates B, Parlakpinar H, Kati B, Karaaslan MG, Acet A: Protective effect of infliximab on ischemia/reperfusion-induced damage in rat kidney. Ren Fail 2012, 34, 1144–1149.
  10. Golembiewska E, Ciechanowski K: Renal tubular acidosis – underrated problem? Acta Biochim Pol 2012, 59, 213–217.
  11. Sun X, Soleimani M, Petrovic S: Decreased expression of Slc26a4 (Pendrin) and Slc26a7 in the kidneys of carbonic anhydrase II-deficient mice. Cell Physiol Biochem 2008, 21, 95–108.
  12. Parkkila S, Rajaniemi H, Parkkila AK, Kivela J, Waheed A, Pastorekova S, Pastorek J, Sly WS: Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci U S A 2000, 97, 2220–2224.
  13. Lapenna D, Ciofani G, Cuccurullo C, Neri M, Giamberardino MA, Cuccurullo F: Bicarbonate-dependent, carbonate radical anion-driven tocopherol-mediated human LDL peroxidation: an in vitro and in vivo study. Free Radic Res 2012, 46, 1387–1392.
  14. Yilmaz M, Tekekoglu S, Herek O, Ozmen O, Sahinduran S, Buyukoglu T: Ameliorative effect of adalimumab on experimentally induced acute pancreatitis in rats. Pancreas 2010, 39, 1238–1242.
  15. Oyar EÖ, Kiriş I, Gülmen S, Ceyhan BM, Cüre MC, Delibaş N, Lortlar N, Okutan H: The protective effect of adrenomedullin on renal injury, in a model of abdominal aorta cross-clamping. Thorac Cardiovasc Surg 2012, 60, 5–10.
  16. Qiao X, Li RS, Li H, Zhu GZ, Huang XG, Shao S, Bai B: Intermedin protects against renal ischemia-reperfusion injury by inhibition of oxidative stress. Am J Physiol Renal Physiol 2013, 304, 112–119.
  17. Devarajan P: Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006, 17, 1503–1520.
  18. Seifi B, Kadkhodaee M, Delavari F, Mikaeili S, Shams S, Ostad SN: Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury. Ren Fail 2012, 34, 610–615.
  19. Hwang HS, Yang KJ, Park KC, Choi HS, Kim SH, Hong SY, Jeon BH, Chang YK, Park CW, Kim SY, Lee SJ, Yang CW: Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2. Nephrol Dial Transplant 2013, 28, 1156–11566.
  20. Zou C, Hu H, Xi X, Shi Z, Wang G, Huang X: Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity. J Surg Res 2013, 184, 1092–1095.
  21. Xu YF, Liu M, Peng B, Che JP, Zhang HM, Yan Y, Wang GC, Wu YC, Zheng JH: Protective effects of SP600125 on renal ischemia-reperfusion injury in rats. J Surg Res 2011, 169, 77–84.
  22. Wagner CA, Devuyst O, Bourgeois S, Mohebbi N: Regulated acid-base transport in the collecting duct. Pflugers Arch 2009, 458, 137–156.
  23. Supuran CT: Carbonic anhydrases – an overview. Curr Pharm Des 2008, 14, 603–614.
  24. Aggarwal M, Boone CD, Kondeti B, McKenna R: Structural annotation of human carbonic anhydrases. J Enzyme Inhib Med Chem 2013, 28, 267–277.
  25. Al-Samir S, Papadopoulos S, Scheibe RJ, Meißner JD, Cartron JP, Sly WS, Alper SL, Gros G, Endeward V: Activity and distribution of intracellular carbonic anhydrase II and their effects on the transport activity of anion exchanger AE1/SLC4A1. J Physiol 2013, 591, 4963–4982.
  26. Stander BA, Joubert F, Tu C, Sippel KH, McKenna R, Joubert AM: Correction: Signaling pathways of ESE-16, an antimitotic and anticarbonic anhydrase estradiol analog in breast cancer cells. PLoS One 2013, 8, 10.
  27. Sowah D, Casey JR: An intramolecular transport metabolon: fusion of carbonic anhydrase II to the COOH terminus of the Cl(–)/HCO(3)(–)exchanger, AE1. Am J Physiol Cell Physiol 2011, 301, 336–346.
  28. Medinas DB, Cerchiaro G, Trindade DF, Augusto O: The carbonate radical and related oxidants derived from bicarbonate buffer. IUBMB Life 2007, 59, 255–262.
  29. Augusto O, Bonini MG, Amanso AM, Linares E, Santos CC, De Menezes SL: Nitrogen dioxide and carbonate radical anion: two emerging radicals in biology. Free Radic Biol Med 2002, 32, 841–859.
  30. Queliconi BB, Marazzi TB, Vaz SM, Brookes PS, Nehrke K, Augusto O, Kowaltowski AJ: Bicarbonate modulates oxidative and functional damage in ischemia-reperfusion. Free Radic Biol Med 2013, 55, 46–53.
  31. Liochev SI, Fridovich I: Bicarbonate-enhanced peroxidase activity of Cu, Zn SOD: Is the distal oxidant bound or diffusible? Arch Biochem Biophys 2004, 421, 255–259.
  32. Berchtold JF, Constable PD, Smith GW, Mathur SM, Morin DE, Tranquilli WJ: Effects of intravenous hyperosmotic sodium bicarbonate on arterial and cerebrospinal fluid acid-base status and cardiovascular function in calves with experimentally induced respiratory and strong ion acidosis. J Vet Intern Med 2005, 19, 240–251.
  33. Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marini A, Pintus G, Nativi C, Richichi B, Scozzafava A, Carta F, Torre E, Supuran CT, Chiarugi P: Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelialmesenchymal transition in prostate carcinoma cells. Cell Cycle 2013, 12, 1791–1801.
  34. Yoshiura K, Nakaoka T, Nishishita T, Sato K, Yamamoto A, Shimada S, Saida T, Kawakami Y, Takahashi TA, Fukuda H, Imajoh-Ohmi S, Oyaizu N, Yamashita N: Carbonic anhydrase II is a tumor vessel endotheliumassociated antigen targeted by dendritic cell therapy. Clin Cancer Res 2005, 11, 8201–8207.
  35. Franz MG, Winkler BC, Norman JG, Fabri PJ, Gower WR Jr: Tumor necrosis factor-alpha induces the expression of carbonic anhydrase II in pancreatic adenocarcinoma cells. Biochem Biophys Res Commun 1994, 205, 1815–1821.
  36. Pathirana D, Nast A, Ormerod AD, Reytan N, Saiag P, Smith CH, Spuls P, Rzany B: On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol 2010, 24, 1458–1467.
  37. Wang XP, Zhang W, Liu XQ, Wang WK, Yan F, Dong WQ, Zhang Y, Zhang MX: Arginase I enhances atherosclerotic plaque stabilization by inhibiting inflammation and promoting smooth muscle cell proliferation. Eur Heart J. 2013. (Epub ahead of print), PubMed PMID: 23999450.
© Wroclaw Medical University